Last updated: 11/07/2018 19:20:22
Long-Term Treatment of Chronic Obstructive Pulmonary Disease with Salmeterol and the Additive Effect of Ipratropium. Extensive searching has revealed that no clinical study report is available for this study.
Clinicaltrials.gov ID
Not applicable
EudraCT ID
Not applicable
EU CT Number
Not applicable
Trial status
Study complete
Study complete
Trial overview
Official title: Long-Term Treatment of Chronic Obstructive Pulmonary Disease with Salmeterol and the Additive Effect of Ipratropium. Extensive searching has revealed that no clinical study report is available for this study.
Trial description: Long-Term Treatment of Chronic Obstructive Pulmonary Disease with Salmeterol and the Additive Effect of Ipratropium. Extensive searching has revealed that no clinical study report is available for this study.
Primary purpose:
Not applicable
Trial design:
Not applicable
Masking:
Not applicable
Allocation:
Not applicable
Primary outcomes:
Not applicable
Secondary outcomes:
Not applicable
Interventions:
Not applicable
Enrollment:
Not applicable
Primary completion date:
Not applicable
Observational study model:
Not applicable
Time perspective:
Not applicable
Clinical publications:
Abstract: Van Noord JA, De Munck DRAJ, Bantje TA, Hop WCJ, Bommer AM. Efficacy and safety of salmeterol (SLM) and ipratropium bromide (IPB) in patients with chronic obstructive pulmonary disease (COPD). Am J Respir Crit Care Med 1998;157(3):A799
van Noord JA, de Munck DR, Bantje TA, et al. Long-Term Treatment of Chronic Obstructive Pulmonary Disease with Salmeterol and the Additive Effect of Ipratropium. Eur Respir J 2000; 15: 878-885.
Inclusion and exclusion criteria
Trial location(s)
This study does not involve prospective enrollment of participants.
Study documents
Scientific result summary
Available language(s): English
If you wish to request for full study report, please contact - [email protected]
Results overview
Not applicable
Recruitment status
Study complete
Actual primary completion date
Not applicable
Actual study completion date
1996-01-11
Plain language summaries
Plain language summaries of clinical trial results for Phase 2-4 clinical trials that were initiated on or after January 2022 will be posted by GSK within one year following study completion.
Additional information about the trial
Not applicable
Participate in clinical trial
Access to clinical trial data by researchers
Visit website